We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.
Raise Finance
CBILS Lenders
Enterprise and Growth Hubs
Looking for a lead investor?
Become a lead investor?
Series A Funding
Ratings Explained
Platform Directory
Carocell Bio
Sep 28th 2020	- May 28th 2021
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
Envestors Medical EIS
Visit Pitch on Envestors	More about Envestors
Carocell Bio Rating Review
Rated on 13/10/2020
Pitch Rated
Insufficient Data
UNRATED*
* Section unrated owing to insufficient or incomplete information available at the time of rating.
Pitch rating powered by CROWDRATING™
pre-money valuation
equity available
pledge per investor
incorporated 4 years
Previous Funding rounds
28 Sep 20 Envestors	 45.00%
Dr Michael John Davies
Appointed: 08-11-2016
What the ratings mean
49% and under
We suggest potential investors carry out further study of their own 50-64%
Room for improvement 65-79%
Worth considering 80%+
Gold rating, our highest rating
Click here for more information on our ratings
Login to view the full report
Skills 73%
Carocell Bio's Management team is led by the Founder/CEO, who has expertise in early-stage development and taking medicines from ideation to the market. He is skilled in clinical development, drug discovery, clinical research, medical education, drug development, pharmacology, and regulatory submissions. The Chairman is an expert in clinical development, biotechnology, cell culture, new business development, strategic leadership, technology transfer, and toxicology. The Marketing Director is well versed in brand development, marketing management, business administration, SEO copywriting, strategic planning, production management, online advertising, and marketing communications. It was noted that they have not, as yet, appointed a dedicated Finance Head and CEO is also taking up the responsibilities of Product Developer in the team.
Visit Pitch on Envestors
More about Envestors
Funding progress
More from Medical
Freehand Crowdcube	Medical	EIS
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
pledged: 160% days to go: 23	investment: £482,450
Address: 28a London Road, Alderley Edge, Cheshire, England
Email: contact@carocellbio.com
Sign in to Nextfin
To enable all of the features of the site and view this pitch on Envestors, please fill in your information below. We are not responsible for the content of the Envestors website and we do not accept any liability. By proceeding to this pitch you are accepting these terms.
Register with Nextfin
New to Nextfin?
Register with Nextfin now!
or sign in with your social media account:
Sign in with Nextfin
To enable all of the features of the site and view this pitch on Envestors, please sign in below.
You are now leaving NextFin for Envestors
We are not responsible for the content of the Envestors website and we do not accept any liability. By proceeding to this pitch you are accepting these terms.
Come back soon as we are listing new investment opportunities each day.
Continue to Envestors	Stay at NextFin
Premium Advert
PREMIUM is a paid for promotion by the pitch / brand owner and does not indicate an endorsement or a recommendation by Nextfin.
Risk Warning - Summary
Investing in equity crowdfunding and early stage businesses involves high risks, which may include long-term investment horizons, illiquidity, lack of income and potential dilution. Any investor needs to be in the position to afford a total loss of capital invested. Investments that are made via Peer to Peer platforms should not be considered deposits like a bank. Your capital is at risk and is not covered by the Financial Service Compensation Scheme (FSCS).
NextFin is targeted at members who have the knowledge and experience to understand these risks and make their own investment decisions. You will NOT invest through NextFin but through the relevant crowdfunding website which also has signed off the content as a Financial Promotion on its own website. NextFin is not the originator of the financial promotions that appear on its site. However we do to the best of our ability carry out limited compliance checks on the originator and the company seeking funding to seek to ensure they are conforming to FCA regulations and anti-money laundering equity/requirements as appropriate. Business Agent Limited, trading as NextFin, takes no responsibility for this information or for any recommendations or opinions made by the companies or its users.
The rating report and any other reports published on NextFin.co.uk do not constitute an offer or a solicitation to buy or sell any securities referred to herein. The rating reports should be used as part of your own research to assess whether or not you should make an assessment and if in doubt seek professional independent advice. Rating reports should not be so construed, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information on this website or in reports or ratings published by Business Agent Ltd, or on which this or any other reports are based, has been obtained from sources that Business Agent Ltd believes to be reliable and accurate. However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. The information or opinions are provided as at the date of this report or any other report publication dates and are subject to change without notice. The information and opinions provided in this and any other reports take no account of the investors/ individual circumstances and should not be taken as specific advice on the merits of any investment decision. Investors should consider any or all of the reports or ratings we publish as only a single factor in making any investment decisions.
Business Agent Ltd does not accept any liability whatsoever for any direct or consequential loss however so arising, directly or indirectly, from any use of this report nor its contents. Investors may receive back less that they invested as investments may fall as well as rise in value. Investors should obtain independent advice based on their own circumstances before making investment decisions. Click here for our full risk warning.
EIS & SEIS
Crowdfunding Records
Issuers Terms & Conditions
The logos and content of each pitch belong to their respective owner. nextfin.uk lists the content for the purpose of review and critique.
Business Agent Limited, trading as NextFin. Business Agent Limited is registered in England & Wales (No: 08819159)
Business Agent Limited is authorised and regulated by the Financial Conduct Authority (FRN: 669880)
Wheatfromchaff Limited trading as CrowdRating is registered in England & Wales (No: 09328942)
Wheatfromchaff Limited is authorised and regulated by the Financial Conduct Authority (FRN: 751017)
Address: 7 Peerglow Centre, Marsh Lane, Ware, Hertfordshire, SG12 9QL - Tel: 01920 486440
© 2021 nextfin.uk, all rights reserved
Investing in the shares of start-up and early-stage companies can be satisfying and financially rewarding. But it is also very risky.
Loss of investment
There is a significant risk that you will lose your investment. Most start-up companies fail, and it can be many years before even the most successful start-up company begins to pay dividends. You are therefore much more likely to lose your investment than you are to see a return of your capital and a profit;
Lack of liquidity
If you make an investment, you will probably not be able to sell it for many years. Although it is sometimes possible to sell shares in a start-up company to other shareholders in the same company, it is much more likely that a share sale will be impossible unless and until the company is listed on a stock exchange or bought by another company. Even the most successful of start-up companies can take years to get to the point where it can be listed or sold;
Your investment will probably be diluted. If you invest, you will receive shares in the company. If the company needs to raise more capital at a later date, it may issue new shares. If those shares are offered to existing investors and you choose not to buy any more shares, your share of the company will decline. Your share of the company will also decline if the company only offers its new shares to new investors. The company might also want or need to offer its new shares on better terms than the terms available on its existing shares. For example, the new shares might have preferential rights to dividends or sale proceeds, a right of first refusal on further share issues, or better voting rights than the existing shares. Each of these things is likely to be to your disadvantage.
Rarity of dividends
Dividends are payments made by a business to its shareholders from the company's profits. Most of the companies pitching for equity are start-ups or early stage companies, and these companies will rarely pay dividends to their investors. This means that you are unlikely to see a return on your investment until you are able to sell your shares. Profits are typically re-invested into the business to fuel growth and build shareholder value. Businesses have no obligation to pay shareholder dividends.
The need for diversification when you invest
Diversification involves spreading your money across multiple investments to reduce risk. However, it will not lessen all types of risk. Diversification is an essential part of investing. Investors should only invest a proportion of their available investment funds and should balance this with safer, more liquid investments
Donations and rewards
Giving money to a company can be satisfying; especially if it's doing – or wants to do – something you think is worthwhile.
However, if you decide to give money to a company and it reaches its minimum target, it will be impossible, or almost impossible, to get it back - even if you change your mind immediately.
Loans and P2P Investments
Lending money to start-up and early-stage companies can be satisfying and financially rewarding. But it is also involves risk including Loss of investment and interest payments, Lack of liquidity, Restricted redemption rights, Unsecured investments and being bottom of the chain to be paid when a business winds up. Most start-ups fail, and it can be many months or years before a successful start-up begins to make enough money to be able repay its debts. There is a significant risk that the company you lend money to:
• Will not be able to pay you back. If the company you lend money to cannot afford to repay you, you will lose some or all of the money you loaned to the company. You will also lose some or all of the interest you expected to receive in return for your loan;
• Will not be able to pay you back on time. If the company you lend money to cannot afford to repay you when the repayments are due, you may have to wait – perhaps for many months or years – to recover the money you loaned to the company and the interest you expected to receive in return for your loan;
• Will become insolvent. If the company you lend money to cannot afford to pay its debts to you or to its other creditors, the company may be wound up, dissolved or put it into receivership, liquidation or administration. If any of these things happen, you may not be able to recover the money you loaned to the company or the interest you expected to receive in return for your loan. You may also have to wait many months or years to recover any payment, and that payment may be much less that you would have been entitled to receive if the company had not become insolvent. This might happen because some of the company's creditors (including the receiver, liquidator or administrator) might be entitled to receive their money before other creditors, and when they have been paid, the company might not have sufficient funds left to pay you.
• Investments that are made via Peer to Peer platforms should not be considered deposits like a bank. Your capital is at risk and is not covered by the Financial Service Compensation Scheme (FSCS).